1. What is mancozeb?• Mancozeb is an ethylene bisdithiocarbamate (EBDC) fungicide, belonging to the group of

dithiocarbamates. It is a non-systemic fungicide, acting on the surface of plants, applied by spraying byprofessional growers.

• It is used on a wide variety of crops in agriculture, professional turf management and horticulture. Mainuses are on potatoes, grapes, apples, onions, and tomatoes.

•than 400 pathogenic fungi.

o

target fungi.

o

blight; downy mildew; cucurbit scab; leaf blotch1.

2. What are the benefits of Mancozeb?•• It has a multi-site action and a broad spectrum of disease coverage.

• after 60 years on the usual diseases.

• It is highlycompatible with other ingredients, which makes it very appropriate for use in mixtures.

• It is not volatile, i.e. it does not vaporize into the air. In addition, it poorly dissolves in water and degradesquickly in soils, which reduces its overall impact on the environment.

• It contains the micronutrients zinc and manganese which enrich the crop.

• It is suitable for Integrated Pest Management (IPM) programmes.

3. EU Regulatory update

1 On basis of trials conducted by the Task Force as of 2008 till present, in the framework of the re-registration procedure

MancozebSafe, Efficacious and Essential for the Grower’s Toolbox

2006 2008 2015 2019 2020

Annex 1inclusion

1st July 2006

Annex IIIDossier

submitted for re-registration by June 2008

AIR Dossier submitted July 2015

CRD Assessment

Report to EFSA August/September

2017

Renewal

Q4 2019

2018

EFSAevaluation starts

May 2018

EFSApublic consultation

Feb - Apr 2018

2017

Art 43 Product Re-authorisation

Q1 2020

Draft ED criteriaproposal June 2016

ED ED criteria

adoptionApril 2018

criteria application

November 2018

4. Renewal authorisation• Mancozeb has been used since 1962 and is currently authorised in 28 EU Member States.

• In 2006, Mancozeb was authorised at EU level (Annex I) and then in 28 EU Member States, on the basis ofe

• Mancozeb’ initial authorisation until 2016 has been extended until 2018 and is up for renewal in 2018.

• In July 2015, the European Mancozeb Task Force submitted a dossier in view of the renewal ofmancozeb’s inclusion in Annex I to the UK Chemicals Regulation Directorate (CRD), the RapporteurMember State.

•

• Receiving the

• The Commission favours the non-establishment of MRLs and Import Tolerances (ITs) for substances banned due

conclusion from EFSA, a decision on the renewal of mancozeb will be taken by theCommission. Concluding this process, the Task Force expects EU authorisation for mancozeb to berenewed by around Q1 2020.

5. Classification•

• 1.

6. Endocrine disrupting properties•

not an endocrine disruptor.

•determination of endocrine disrupting properties to be unworkable in its current form.

• The Commission must adopt robust, proportionate and science based criteria.

• These criteria have to maintain the existing high levels of protection for human health and theenvironment, while ensuring EU farmers have access to the essential crop protection products.

• The lack of inclusion of potency and other relevant aspects of hazard characterisation is a majoromission. These aspects are critical to distinguish between substances which pose a real danger tohealth and the environment and those that do not.

•the

that the assessment of mancozeb in light of the additional information provided will conclude that mancozeb is safe for use.

3.1

3.2

3.3

1 Studies conducted by the Task Force and independent published studies.

in

Please contact Barnali James, European Regulatory Affairs at UPL Europe Ltd and European Mancozeb Task Force leader, at bgoswami@uniphos.com

MANCOZEB IS A WIDELY USED AND HIGHLY VALUED ACTIVE SUBSTANCE USED FOR THE CONTROL OF BOTH LATE AND EARLY BLIGHT IN POTATO

THE POTENTIAL LOSS OF MANCOZEB IN TERMS OF COST, VOLUME AND REVENUE

The combined impact of reduced yields and increased costs

of production will cost the EU

Yield impacts could result in reduced potato production

0.69 - 4.8 million tonnes per year, worth between

103 - 845 € million

Increased cost of production of between

68 -146 € million

171 - 994 € million

EQUIVALENT IMPACT EU-28

Reduction in production in tonnes

Average reduction in gross margin in low and high blight pressure in € million

Increase in production cost in € million

MAIN BENEFITS Safe

Cost effective

Multisite mode of action

No reported resistance

Effectiveafter 60 years

High compatibilityfor mixtures

This factsheet is produced by the Mancozeb Task Force, a joint activity of UPL Europe Ltd and Indofil Industries Ltd as notifiers of the active substance Mancozeb.

ADAS report , “the economic value of mancozeb to the European potato industry for the control of potato blight” , 2015

8 EU MEMBER STATEs

87-507 M 2,980,000 T 35-75 M

61% OF EU POTATO PRODUCTION

FRANCE4-88 M496,000 T

GREECE6-38 M83,000 T

ITALY0,6-4 M16,000 T

IRELAND3-14 M61,000 T

SPAIN3-34 M108,000 T

NETHERLANDS3-44 M222,000 T

UK4-56 M223,000 T

GERMANY62-247 M1,822,000 T

MancozebSafe, Efficacious and Essential for the Grower’s Toolbox